IPO

News

Sleep apnoea drug firm Apnimed files for IPO

Apnimed has joined the IPO queue on the Nasdaq, hoping to raise additional funding for its late-stage oral therapy for obstructive sleep apnoea.

News

Kalohexis chief executive Russell Potterfield

Obesity biotech Kalohexis files confidential IPO

Just weeks after forming as a spinout from Endevica Bio, obesity drug developer Kalohexis has filed for an IPO.

News

Scribe Therapeutics joins the IPO queue

Scribe Therapeutics has become the latest biotech to announce plans to list on the Nasdaq as it advances its spin on CRISPR-based therapeutics.

News

Heart drug biotech Kardigan raises $400m in upscaled IPO

Cardiovascular drug developer Kardigan has completed its IPO, raising substantially more than it originally anticipated.

News

Cancer biotech Parabilis books record IPO, raising $670m

Parabilis has broken the IPO record set by Kailera in April, packing its coffers as it starts an ambitious trial programme for lead drug zolucatetide.

News

Parabilis prices IPO at an ambitious $475 million

Parabilis has set the terms of its IPO, seeking to raise a hefty $475m for phase 3 trials of its lead drug for desmoid tumours.

Sleep apnoea drug firm Apnimed files for IPO

Obesity biotech Kalohexis files confidential IPO

Scribe Therapeutics joins the IPO queue

Heart drug biotech Kardigan raises $400m in upscaled IPO

Cancer biotech Parabilis books record IPO, raising $670m

Parabilis prices IPO at an ambitious $475 million

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

IPO

Editor's Picks